Palvella Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Palvella Therapeutics, Inc. (PVLA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 500.00 thousand shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2024-11-13
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 500.00K shares, a 16.67% decline year-over-year.
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 600.00K shares, a 98.48% decline year-over-year.
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-03-31 was 39.40M shares, a 2.07% increase year-over-year.
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-03-31 was 38.60M shares, a 10.60% increase year-over-year.
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 39.40M shares, a 2.60% increase from fiscal 2022.
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 38.40M shares, a 4.35% increase from fiscal 2021.
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 36.80M shares, a 0.54% decline from fiscal 2020.
- Palvella Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 37.00M shares, a 10.78% increase from fiscal 2019.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | 500.00K shares 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | 500.00K shares 10-Q · filed 2024-08-14 | ||||||
| 2024-03-31 | 500.00K shares 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | 39.40M shares 10-K · filed 2024-03-29 | ||||||
| 2023-09-30 | 500.00K shares 10-Q · filed 2024-11-13 | 41.00M shares 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | 41.20M shares 10-Q · filed 2023-08-10 | ||||||
| 2023-03-31 | 600.00K shares 10-Q · filed 2024-05-15 | 40.90M shares 10-Q · filed 2023-05-11 | |||||
| 2022-12-31 | 38.40M shares 10-K · filed 2024-03-29 | ||||||
| 2022-09-30 | 38.80M shares 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | 39.60M shares 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 39.40M shares 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | 36.80M shares 10-K · filed 2023-03-31 | ||||||
| 2021-09-30 | 36.70M shares 10-Q · filed 2022-11-04 | ||||||
| 2021-06-30 | 36.50M shares 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 38.60M shares 10-Q · filed 2022-05-11 | ||||||
| 2020-12-31 | 37.00M shares 10-K · filed 2022-03-02 | ||||||
| 2020-09-30 | 37.30M shares 10-Q · filed 2020-11-04 | 37.30M shares 10-Q · filed 2021-11-02 | |||||
| 2020-06-30 | 37.30M shares 10-Q · filed 2020-08-10 | 37.30M shares 10-Q · filed 2021-08-05 | |||||
| 2020-03-31 | 34.90M shares 10-Q · filed 2021-05-17 | ||||||
| 2019-12-31 | 33.40M shares 10-K · filed 2021-03-31 | ||||||
| 2019-09-30 | 21.70M shares 10-Q · filed 2020-11-04 | 21.70M shares 10-Q · filed 2019-11-12 | |||||
| 2019-06-30 | 21.60M shares 10-Q · filed 2020-08-10 | 21.60M shares 10-Q · filed 2019-08-09 | |||||
| 2019-03-31 | 21.60M shares 10-Q · filed 2020-05-11 | ||||||
| 2018-12-31 | 14.70M shares 10-K · filed 2020-03-13 | ||||||
| 2018-09-30 | 14.70M shares 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | 14.70M shares 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | 14.70M shares 10-Q · filed 2019-05-10 | ||||||
| 2017-12-31 | 15.90M shares 10-K · filed 2019-03-18 | 14.40M shares 10-K · filed 2018-03-15 | |||||
| 2017-09-30 | 15.70M shares 10-Q · filed 2018-11-07 | ||||||
| 2017-06-30 | 3.60M shares 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | 11.20M shares 10-Q · filed 2018-05-10 | ||||||
| 2016-12-31 | 8.20M shares 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |